Modern approach to infusion therapy of pregnant women with gestational hypertension

O.V. Vaskiv; A.P. Grigorenko; O.G. Gorbatyuk; A.S. Shatkovska; A.M. Binkovska; I.A.  Priymak

doi:10.26641/2307-0404.2023.1.276021

Authors

O.V. Vaskiv Vinnytsia National Pirogov Memorial Medical University, Ivan Puliuy str., 6, Khmelnytskyi, 29016, Ukraine https://orcid.org/0000-0001-6310-5692
A.P. Grigorenko Vinnytsia National Pirogov Memorial Medical University, Ivan Puliuy str., 6, Khmelnytskyi, 29016, Ukraine https://orcid.org/0000-0003-3184-5359
O.G. Gorbatyuk Vinnytsia National Pirogov Memorial Medical University, Ivan Puliuy str., 6, Khmelnytskyi, 29016, Ukraine https://orcid.org/0000-0002-0123-367X
A.S. Shatkovska Vinnytsia National Pirogov Memorial Medical University, Ivan Puliuy str., 6, Khmelnytskyi, 29016, Ukraine https://orcid.org/0000-0002-3638-8882
A.M. Binkovska Vinnytsia National Pirogov Memorial Medical University, Ivan Puliuy str., 6, Khmelnytskyi, 29016, Ukraine https://orcid.org/0000-0002-6718-4882
I.A. Priymak Vinnytsia National Pirogov Memorial Medical University, Ivan Puliuy str., 6, Khmelnytskyi, 29016, Ukraine https://orcid.org/0000-0001-9933-3371

DOI:

https://doi.org/10.26641/2307-0404.2023.1.276021

Keywords:

fetoplacental dysfunction, gestational hypertension, treatment

Abstract

To date, there are no effective treatment for placental dysfunction in pregnant women with gestational hypertension. Therefore, the purpose of our study was to investigate the clinical efficacy of proposed method of infusion therapy for pregnant women with gestational hypertension, which included a complex of drugs: pentoxifylline, arginine hydrochloride with levocarnitine and rheosorbilact. We observed 73 pregnant women with single fetation, starting from 28 weeks of gestation, who were observed before and during childbirth, and in the postpartum period by the time of discharge from the hospital. All examined women were divided into 3 groups. The first group included 30 pregnant women with gestational hypertension, who received (along with the basic therapy of methyldopa drugs) a complex of infusion solutions: pentoxifylline 0.05% – 100 ml; solution containing arginine hydrochloride 4.2% and levocarnitine 2.0% – 100 ml; reosorbilact preparation – 100 ml. The infusion was carried out once a day in the specified sequence for 10 days. The second group included 20 patients with gestational hypertension on basic therapy with methuldopa only. The control group included 23 women with physiological pregnancy. The data of our study show that in patients receiving the proposed infusion therapy there was a significant decrease in the development of placental dysfunction by 38.3%, the threat of premature birth – by 18.3% and fetal distress – by 30.0%, premature rupture of the membranes – by 35.0%, weakness of labor – by 28.3%, a decrease in the risk of perinatal central nervous system damage – by 33.3% and the frequency of cephalohematomas – by 30.0% compared with women who received only antihypertensive therapy.

References

Avakov VE, Sayipov RM, Davydov DV, Begmatov S, Bazarov A. [Detoxifying Properties of Reosorbilact and Its Effects on Hemostasis]. Emergency medicine. 2014;2(57):47-51. Russian. doi: https://doi.org/10.22141/2224-0586.2.57.2014.83096

Avramenko TV, Kolomiichenko TV, Yaniuta Saar M. [The use of Tivortin in the complex treatment of pregnant women with chronic arterial hypertension]. Health of woman. 2012;4(70):76-80. Ukrainian.

Ventskivskyi BM, Bila VV, Strashko IV, Zahorodnia ОS. [Clinical efficacy of pentoxifylline in the treatment of pregnant women with preterm premature rupture of membranes]. Actual Problems of Pediatrics, Obstetrics and Gynecology. 2017;1:42-6. Ukrainian. doi: https://doi.org/10.11603/24116-4944.2017.1.7356

Lapovets LYe, et al. [Clinical laboratory diagnostics]. Кyiv: Меdytsyna; 2019. 472 p. Ukrainian.

Меrts E. [Ultrasound diagnostics in obstetrics and gynecology. Vol. 1. Obstetrics]. МЕDрRеss-inform; 2016. 720 p. Russian.

Rebrova OYu. [Statistical analysis of medical data. Application of Statistica applications]. MediaSfera; 2018. 312 p. Russian.

Horbatiuk OH, Shatkovska AS, Hryhorenko AP, inventors; Vinnyts. nats. med. іn-t im. M.I. Pyrohova, assignee. [The method of restoring the function of the placenta in pregnant women with fetoplacental dysfunction against the background of pre-eclampsia]. Ukraine patent u201809586. 2019 Feb 25. Ukrainian.

Acharya S, Yasmin E, Balen AH. The use of a combination of pentoxifylline and tocopherol in women with a thin endometrium undergoing assisted conception therapies – a report of 20 cases. Hum Fertil (Camb). 2019;12:198-203. doi: https://doi.org/10.3109/14647270903377178

Azimi A, Ziaee SM, Farhadi P, Sagheb MM. Hypothesis: Pentoxifylline explores new horizons in treatment of preeclampsia. Med Hypotheses. 2015;85:468-74. doi: https://doi.org/10.1016/j.mehy.2015.06.031

Dorniak-Wall T, Grivell RM, Dekker GA, et al. The role of L-arginine in the prevention and treatment of pre-eclampsia: a systematic review of randomised trials. Journal of Human Hypertension. 2014;28:230-5. doi: https://doi.org/10.1038/jhh.2013.100

Griffin M, Heazell AE, Chappell LC, Zhao J, Lawlor DA. The ability of late pregnancy maternal tests to predict adverse pregnancy outcomes associated with placental dysfunction (specifically fetal growth restriction and preeclampsia): a protocol for a systematic review and meta-analysis of prognostic accuracy studies. Systematic Reviews. 2020;9(1):78. doi: https://doi.org/10.1186/s13643-020-01334-5

Safarova S, Aliyeva E, Abbasova F, Mirzoyeva K. [The Experience of L-Arginine Using in Placental Insufficiency]. Infusion & Chemotherapy. 2020;3.1:67-8. Russian. doi: https://doi.org/10.32902/2663-0338-2020-3.1-56

Schoots MH, Gordijn SJ, Scherjon SA, van Goor H, Hillebrands JL. Oxidative stress in placental pathology. Placenta. 2018;69:153-61. doi: https://doi.org/10.1016/j.placenta.2018.03.003

Tomimatsu T, Mimura K, Endo M, Kumasawa K, Kimura T. Pathophysiology of preeclampsia: an angio-genic imbalance and longlasting systemic vascular dysfunction. Hypertension Research. 2017;40(4):305-10. doi: https://doi.org/10.1038/hr.2016.152

Tomimatsu T, Mimura K, Matsuzaki S, Endo M, Kumasawa K, Kimura T. Preeclampsia: Ma¬ternal Syste-mic Vascular Disorder Caused by Generalized Endothelial Dysfunction Due to Placental Antiangiogenic Factors. International Journal of Molecular Science. 2019;20(17):42-6. doi: https://doi.org/10.3390/ijms20174246